Advertisement

Topics

Search Results for "Dabur Sanat Pharma"

12:18 EST 24th February 2017 | BioPortfolio

Matching Channels

Datamonitor - aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapidly evolving marketplace

The Datamonitor Group aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapi...

Laboratory

Labs are the hub of much of modern medicine, either in the hospital setting processing patients blood tests and other samples, in research institutions at many universities or in the headquarters of...

Eligard

Eligard® is a hormone compound for the treatment of advanced, hormone-dependent prostate cancer. The active ingredient (leuprolide acetate) significantly reduces the level of the male sex hormon...

Zyme Communications

Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value, and generate interest from commercial leads...

Biosuperior Antibodies

After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of...

Matching News

Fresenius Kabi Oncology, Ltd. formerly Dabur Pharma Limited Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350

SummaryMarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an orga...

Fosun’s Yao Pharma invests big in global reach, by Wang Fangqing

As a major member of Fosun Pharma family, Chongqing-based Yao Pharma is a key part of Fosun Pharma’s…

VERONA PHARMA PLC - Issue of Equity

PR NewswireLondon, December 29 Verona Pharma plc ("Verona Pharma" or the "Company") Exercise of Options Verona Pharma plc (AIM: VRP), the drug development company focused on first-in-class medicin...

NASDAQ OMX Nordic: Derivatives: Anticipated adjustment in Karo Pharma due to rights issue (02/17)

The following information is based on a press release from Karo Pharma AB (Karo Pharma) published on January 16, 2017 and may be subject to change. The board of Karo Pharma has proposed that the Ex...

Big Pharma Sues Big Pharma in Biosimilar Cases

With the number of pharma lawsuits growing quickly, lawyers say the legal landscape has recently gotten a lot more complex

Tetra Bio-Pharma Inc. Announces a New Appointment to its Scientific and Clinical Advisory Board

OTTAWA, ONTARIO -- (Marketwired) -- 01/11/17 -- PhytoPain Pharma Inc. ("PhytoPain Pharma" or "PPP"), a subsidiary of Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(OTC PI...

Tetra Bio-Pharma Inc. Announces that its Phase I Trial of Inhaled Marijuana in Healthy Volunteers Will Be Performed by Algorithme Pharma, an Altasciences Company

OTTAWA, ONTARIO -- (Marketwired) -- 09/29/16 -- Tetra Brio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN), through its wholly-owned subsidiary, PhytoPain Pharma Inc. ("PPP"), a pha...

Mezzion hires Pol Pharma and Halo Pharma and accuses Dr Reddy's of fraud

Mezzion has hired Pol Pharma and Halo Pharma and accused former CMO Dr Reddy’s of hiding manufacturing problems that cost its erectile dysfunction candidate, udenafil, US approval.

Matching PubMed Articles

The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance.

In the context of increased pharmaceutical innovation deficits and Big Pharma blockbusters' patent expirations, this paper examines the moderating role of firms' absorptive capacity in external innova...

Scratching the Career Itch Leads To Bigger Reach in Pharma.

A Review of "Big Pharma, Women, and the Labour of Love"by Thea Cacchioni. Toronto, Canada: University of Toronto Press, 2015, 167 pages, $50.00 (hardcover), $21.95 (paperback), $20.85 (Kindle).

AMCP Seeks an End to 20 Years Of Confusion Over FDAMA Section 114.

The FDA never issued regulations to clarify the boundaries of promotion of pharmacoeconomic data, something it's been dragging its feet on for nearly 20 years. In turn, pharma companies, fearful of be...

▼Pitolisant for narcolepsy.

▼Pitolisant (Wakix-Bioprojet Pharma) is a new treatment for adults with narcolepsy with or without cataplexy. It was licensed for use in the EU in March last year and has orphan drug status.(1) Here...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement